Specialty Pharma Journal Specialty, Precision & Technology
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), …
Tag Archives: DMARDs
May, 2017
January, 2017
-
16 January
FDA Extends Review Period for Investigational Rheumatoid Arthritis Drug Baricitinib
INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate …
April, 2015
-
22 April
Even After the Introduction of Biosimilars in the US, RA Patients May Still Face High Cost Burden
An investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that starting these drugs can cost Medicare patients more than $2,700 in co-payments a year, and patients may continue to face a high cost burden even with the introduction of biosimilars. Results from a new study, published in …